Table 2.

CD34 and CD61 glycoprotein expressions implied in cell proliferation in prostate adenocarcinoma, benign prostatic hyperplasia, and non-malignant adjacent tissue samples.

Number	Parameters	Control X ± SD	PCa X ± SD	Control X ± SD	BPH X ± SD
1	CD61T	86.90 ± 4.39 *	70.59 ± 15.30 *	86.90 ± 4.39	91.15 ± 4.76
	p values	0.019		0.273
2	CD34 + CD61+	16.15 ± 2.58 **	28.79 ± 10.14 **	16.15 ± 2.58 *	40.65 ± 11.88 *
	p values	0.005		0.019
3	CD61+	16.26 ± 2.52 **	37.81 ± 16.21 **	16.26 ± 2.52 **	36.50 ± 13.55 **
	p values	0.000		0.002
4	CD61-	83.49 ± 2.72 **	59.89 ± 17.38 **	83.49 ± 2.72 **	62.49 ± 13.57 **
	p values	0.000		0.001
5	CD34T	87.29 ± 5.20	75.43 ± 14.20	87.29 ± 5.20	90.55 ± 6.38
	p values	0.090		0.532
6	CD34+	54.49 ± 0.72	57.81 ± 14.22	54.49 ± 0.72 **	66.31 ± 11.28 **
	p values	0.369		0.009
7	CD34-	45.25 ± 0.52	39.95 ± 13.36	45.25 ± 0.52 **	32.69 ± 11.30 **
	p values	0.136		0.007

Legend: X, obtained results mean; SD, standard deviation; PCa, prostate adenocarcinoma; BPH, benign prostatic hyperplasia; CD61 T, total CD61 glycoproteins expression; CD34 T, total CD34 glycoproteins expression; ** p ≤ 0.01 and * p < 0.05 represent statistically significant differences between controls and experimental samples made by independent t test.